NCT03083041 2026-03-03
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
Clinical Trials
7 trialsNCT05387512 2026-01-06
A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer
Affiliated Hospital of Nantong University
Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05156970 2025-07-31
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed